Cerebrospinal Fluid Proteomics Study On Prognostic Differences In Epidemic Encephalitis B Patients

Objective: This study investigated the changes in protein levels in cerebrospinal fluid(CSF)of EEB patients by label-free quantitative proteomics techniques,and screened and validated potential biomarkers that may be used as early disease diagnosis;To study the changes in protein levels between two subtypes of mild epidemic encephalitis B(MEEB)and severe epidemic encephalitis B(SEEB),and to screen for biomarkers associated with clinical prognosis that may exist between different subtypes,thereby further Provide a theoretical basis for describing its pathogenesis and improving prognosis.Methods: In this study,EEB was divided into two subtypes,MEEB and SEEB,according to different clinical prognosis in the clinic.By label-free quantitative proteomics method,gel electrophoresis was combined with quadrupole-classical orbitrap-linear ion trap.Combining mass spectrometry(Lumos)technology,firstly analyze the CSF proteome of EEB patients,screen and verify the biomarkers that may be used as disease diagnosis,and then perform proteome analysis,screening and EEB on different subtypes of EEB MEEB and SEEB.Biomarkers associated with disease typing and clinical prognosis.Results: Compared with the Control group,the EEB group found 59 differential proteins with fold change greater than 3 and p value less than 0.05.The main factors involved in biological processes were immune response,cell adhesion,central nervous system development,brain development,and neuronal recognition.Compared with the Control group,MEEB and SEEB share 35 differential proteins,the fold change is greater than 3 and the p value is less than 0.05.The biological processes involved are immune response,neuron recognition,etc.MEEB is compared with SEEB.There were 31 differential proteins with a fold change greater than 3 and a p-value less than 0.05.The biological processes involved were regulation of endopeptidase activity,proteolysis and central nervous system development.Conclusion: Up-regulation of peptidase activity in CSF and down-regulation of peptidase inhibitor activity may lead to differences between MEEB and SEEB.CTSB,PEBP1,TIMP1 may be biomarkers of MEEB and SEEB.